高级搜索
顺铂联合白细胞介素-2治疗恶性胸腔积液的研究[J]. 肿瘤防治研究, 2011, 38(08): 937-939. DOI: 10.3971/j.issn.1000-8578.2011.08.021
引用本文: 顺铂联合白细胞介素-2治疗恶性胸腔积液的研究[J]. 肿瘤防治研究, 2011, 38(08): 937-939. DOI: 10.3971/j.issn.1000-8578.2011.08.021
Cisplatin Combined with Interleukin-2 to Treat Malignant Pleural Effusion[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 937-939. DOI: 10.3971/j.issn.1000-8578.2011.08.021
Citation: Cisplatin Combined with Interleukin-2 to Treat Malignant Pleural Effusion[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 937-939. DOI: 10.3971/j.issn.1000-8578.2011.08.021

顺铂联合白细胞介素-2治疗恶性胸腔积液的研究

Cisplatin Combined with Interleukin-2 to Treat Malignant Pleural Effusion

  • 摘要: 目的观察胸腔内注入顺铂与白细胞介素-2治疗恶性胸腔积液的有效性和安全性。方法60例恶性胸腔积液患者的治疗用顺铂联合白细胞介素-2(A组)23例,单用顺铂(B组)19例, 单用白细胞介素-2(C组)18例。用一次性中心静脉导管行胸腔置管和闭式引流胸腔积液,A组注入顺铂40~60 mg+白细胞介素-2 100万u,B组注入顺铂60 mg,C组注入白细胞介素-2 100万u,1次/周,连续注射2~3周,4周后观察两组的疗效及不良反应。结果A、B、C三组总有效率分别82.6%、68.4%、66.7%;生活质量提高,KPS评分改善率为82.6% 、78.9% 、77.8% ;三组不良反应无显著差异。结论胸腔闭式引流后灌注顺铂联合白细胞介素-2治疗恶性胸腔积液的疗效优于单用顺铂及单用白细胞介素-2,且不良反应轻。

     

    Abstract: ObjectiveTo evaluate the efficacy and safety of cisplatin(PPD) plus interleukin-2(IL-2) to therapy malignant pleural effusion.MethodsSixty patients with malignant pleural effusion were divided into three groups:A group (n=23) injected by 40~60 mg of PPD and 1 000 000 units of IL-2,B group (n=19) injected with 60 mg PPD,C group (n=18) injected with 1 000 000 units of IL-2.The doses were given one time every week, for 2~ 3 weeks.The therapeutic effect and adverse reactions were observed after four weeks.ResultsThe total effective rates in the treatment group A,B and C were respectively 82.6%,68.4% and 66.7% respectively,and quality of life and KPS score improvement rate was 82.6%, 78.9%and 77.8%. Side effects were no significant difference among 3 groups. ConclusionPPD combined with IL-1 was efficacy and safety in the treatment of patients with malignant pleural effusions.

     

/

返回文章
返回